Role of interleukin-23 circulating levels increase in resected colorectal cancer before and after chemotherapy: Preliminary data and future perspectives

Journal of Cellular Physiology

Volumn 226, Issue 11, 2011, Pages 3032-3034

  Adamo, V ^a   Franchina, T ^a   Minciullo, P L ^a   Pace, E ^b   Colonese, F ^a   Ricciardi, G R R ^a   Saitta, S ^a   Ferraro, M ^b   Spatari, G ^a   Gangemi, S ^a,b  

^a UNIVERSITY OF MESSINA   (Italy)

^b CNR Consiglio Nazionale delle Ricerche   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; INTERLEUKIN 23;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COLORECTAL CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; HUMAN; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; INTERLEUKIN-23; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 80051927375     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22653     Document Type: Article

References (16)

1. Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL. 2003. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 278: 1910-1914.
2. Belladonna ML, Renauld JC, Bianchi R, Vacca C, Fallarino F, Orabona C, Fioretti MC, Grohmann U, Puccetti P. 2002. IL-23 and IL-12 have overlapping, but distinct, effects on murine dendritic cells. J Immunol 168: 5448-5454.
3. Center MM, Jernal A, Smith RA, Wand E. 2009. Worldwide variation in colorectal cancer. CA Cancer J Clin 59: 366-378.
4. Ji Y, Zhang W. 2010. Th17 cells: Positive or negative role in tumor? Cancer Immunol Immunother 59: 978-979.
5. Kaiga T, Sato M, Kaneda H, Iwakura Y, Takayama T, Tahara H. 2007. Systemic administration of IL-23 induces potent antitumor immunity primarily mediated through Th1-type response in association with the endogenously expressed IL-12.
6. Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K, Basham B, McClanahan T, Kastelein RA, Oft M. 2006. IL-23 promotes tumor incidence and growth. Nature 442: 461-465.
7. Liu ZJ, Yadav PK, Su JL, Wang JS, Fei K. 2009. Potential role of Th17 cells in the pathogenesis of inflammatory bowel disease. World J Gastroenterol 15: 5784-5788.
8. Lo CH, Lee SC, Wu PY, Pan WY, Su J, Cheng CW, Roffler SR, Chiang BL, Lee CN, Wu CW, Tao MH. 2003. Antitumor and antimetastatic activity of IL-23. J Immunol 171: 600-607.
9. Lubberts E. 2008. IL-17/Th17 targeting: On the road to prevent chronic destructive arthritis? Cytokine 41: 84-91.
10. Lyakh L, Trinchieri G, Provezza L, Carra G, Gerosa F. 2008. Regulation of interleukin-12/interleukin-23 production and T-helper 17 response in humans. Immunol Rev 226: 112-131.
11. Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, Vega F, Yu N, Wang J, Singh K, Zonin F, Veisberg E, Churakova T, Liu M, Gorman D, Wagner J, Zurawski S, Liu Y, Abrams JS, Moore KW, Rennick D, de Waal-Malefyt R, Hannum C, Bazan JF, Kastelein RA. 2000. Novel p19 protein engages IL-12p40 to form a cytokin, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13: 715-725.
12. Shan BE, Hao JS, Li QX, Tagawa M. 2006. Antitumor activity and immune enhancement of murine interleukin-23 expressed in murine colon carcinoma cells. Cell Mol Immunol 3: 47-52.
13. Shen W, Durum SK. 2010. Sinergy of IL-23 and Th17 cytokines: New light in inflammatory bowel disease. Neurochem Res 35: 940-946.
14. Shimozato O, Ugai S, Chiyo M, Takenobu H, Nagakawa H, Wada A, Kawamura K, Yamamoto H, Tagawa M. 2006. The secreted form of the p40 subunit of interleukin (IL)-12 inhibits IL-23 functions and abrogates IL-23-mediated antitumour effects. Immunology 117: 22-28.
15. Stanilov N, Miteva L, Mintchev N, Stanilova S. 2009. High expression of Foxp3, IL-23p19 and survivin mRNA in colorectal carcinoma. Int J Colorectal Dis 24: 151-157.
16. Wang YQ, Ugai S, Shimozato O, Yu L, Kawamura K, Yamamoto H, Yamaguchi T, Saisho H, Tagawa M. 2003. Induction of systemic immunity by expression of interleukin-23 in murine colon carcinoma cells. Int J Cancer 105: 820-824.